风湿性心脏病并发心房颤动患者应用胺碘酮治疗的安全性

摘要

目的：探讨风湿性心脏病并发心房颤动患者在临床上使用胺碘酮治疗的效果。方法选取2014年3月—2015年8月期间该院风湿性心脏病并发心房颤动患者150例,将其随机数字表分对照组(常规临床给药)、观察组(常规联合胺碘酮治疗),各75例,对比2组ICU监护、住院时间,术后窦性心律维持情况等各项指标的数据。结果观察组的ICU监护平均(1.59±1.52)d、住院平均天数(10.26±1.75)d,术后7~30 d的窦性心律维持情况(61.33%、57.33%、53.33%)优于对照组,P<0.05。结论应用胺碘酮治疗风湿性心脏病并发心房颤动的效果可观。%Objective To observe the effect of amiodarone on the patients with rheumatic heart disease complicated with a-trial fibrillation. Methods In our hospital from rheumatic heart disease with atrial fibrillation in 150 patients (March 2014 to August 2015), were randomly divided into control group (routine treatment) and observation group (routine combined amiodarone), each of 75 cases, compared 2 groups of data. Results Observation group of ICU monitoring average (1.59± 1.52) d, the average hospital stay (10.26 ±1.75) d, postoperative 7~30 d of sinus rhythm maintenance (61.33%, 57.33%, 53.33%) is better than the control group,P<0.05. Conclusion The effect of amiodarone in the treatment of rheumatic heart disease complicated with atrial fibrillation.